Cheng, Y., Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., . . . Zhu, J. Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. Wiley.
Chicago Style (17th ed.) CitationCheng, Ying, et al. Effect of Anlotinib as a Third‐ or Further‐line Therapy in Advanced Non‐small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial. Wiley.
MLA (9th ed.) CitationCheng, Ying, et al. Effect of Anlotinib as a Third‐ or Further‐line Therapy in Advanced Non‐small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial. Wiley.
Warning: These citations may not always be 100% accurate.